GeoVax Labs (NASDAQ:GOVX) Announces Quarterly Earnings Results, Beats Expectations By $1.19 EPS

GeoVax Labs (NASDAQ:GOVX) announced its quarterly earnings results on Monday. The company reported ($0.97) EPS for the quarter, beating analysts’ consensus estimates of ($2.16) by $1.19, FiscalAI reports.

GeoVax Labs Stock Down 4.4%

Shares of GOVX stock opened at $0.73 on Wednesday. The firm has a market cap of $2.52 million, a P/E ratio of -0.04 and a beta of 3.68. The company has a 50 day moving average of $1.50 and a 200-day moving average of $1.80. GeoVax Labs has a 12-month low of $0.64 and a 12-month high of $20.62.

Wall Street Analyst Weigh In

A number of research firms recently commented on GOVX. Weiss Ratings reissued a “sell (e+)” rating on shares of GeoVax Labs in a research report on Friday, July 17th. D. Boral Capital reaffirmed a “hold” rating on shares of GeoVax Labs in a report on Thursday, April 16th. Finally, Wall Street Zen upgraded shares of GeoVax Labs from a “sell” rating to a “hold” rating in a research note on Sunday, June 21st. One investment analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Reduce” and an average target price of $150.00.

Hedge Funds Weigh In On GeoVax Labs

Institutional investors and hedge funds have recently bought and sold shares of the company. Jane Street Group LLC bought a new stake in shares of GeoVax Labs in the first quarter valued at $27,000. Armistice Capital LLC bought a new position in shares of GeoVax Labs during the 3rd quarter worth $253,000. Renaissance Technologies LLC purchased a new stake in GeoVax Labs in the 4th quarter worth about $104,000. Finally, HRT Financial LP purchased a new stake in GeoVax Labs in the 4th quarter worth about $31,000. 6.09% of the stock is owned by institutional investors.

About GeoVax Labs

GeoVax Labs, Inc is a clinical-stage biotechnology company focused on the development of novel vaccines and immunotherapies against infectious diseases. Leveraging a proprietary Modified Vaccinia Ankara (MVA) viral vector platform, GeoVax aims to induce robust and durable immune responses by expressing virus-like particles (VLPs) in vaccinated individuals. The company’s pipeline encompasses vaccine candidates for HIV, Ebola, Lassa, Zika, MERS and emerging coronaviruses, reflecting a commitment to addressing high-priority global public health threats.

The cornerstone of GeoVax’s technology is its MVA-VLP platform, which combines the safety profile of a non-replicating poxvirus vector with the potent antigen presentation of VLPs.